Storyline
FDA grants priority voucher for higher-dose Wegovy, speeding Novo Nordisk's approval
Novo Nordisk has secured FDA approval for a higher dose of its obesity drug Wegovy, benefiting from a rare priority review voucher that accelerated clearance to just 54 days.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- BioPharma Divebiopharmadive.com
- FDA approves higher Wegovy dose via 4th priority voucherpharmaphorum
- Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it s...Fierce Pharma (All)